Seema Sharma

Ms. Seema Sharma

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
SSSeema Sharma
Seema Sharma
NTNishnat Tiwari
Nishnat Tiwari
STSAMPAT SINGH TANWAR
SAMPAT SINGH TANWAR

10 March 2025 in The Egyptian Heart Journal
Verified
Journal Article
Open access
PDF file
STSampat Singh Tanwar
Sampat Singh Tanwar
SDSumeet Dwivedi
Sumeet Dwivedi
SKSheema Khan
Sheema Khan
SSSeema Sharma
Seema Sharma
Background: Cardiomyopathy is a heterogeneous group of myocardial disorders characterized by structural and functional abnormalities of the heart muscle. It is classified into primary (genetic, mixed, or acquired) and secondary categories, resulting in various phenotypes including dilated, hypertrophic, and restrictive patterns. Hypertrophic cardiomyopathy, the most common primary form, can cause exertional dyspnea, presyncope, and sudden cardiac death. Dilated cardiomyopathy typically presents with heart failure symptoms, while restrictive cardiomyopathy is rarer and often associated with systemic diseases. Diagnosis involves a comprehensive evaluation including history, physical examination, electrocardiography, and echocardiography. Treatment options range from pharmacotherapy and lifestyle modifications to implantable cardioverter-defibrillators and heart transplantation in refractory cases. Main body: Anthracyclines, particularly doxorubicin, have emerged as crucial components in cancer treatment, demonstrating significant antitumor activity across various malignancies. These drugs have become standard in numerous chemotherapy regimens, improving patient outcomes. However, their use is associated with severe cardiotoxicity, including cardiomyopathy and heart failure. The mechanisms of anthracycline action and toxicity are complex, involving DNA damage, iron-mediated free radical production, and disruption of cardiovascular homeostasis. Doxorubicin-induced cardiomyopathy (DIC) is a severe complication of cancer treatment with a poor prognosis and limited effective treatments. The pathophysiology of DIC involves multiple mechanisms, including oxidative stress, inflammation, mitochondrial damage, and calcium homeostasis disorder. Despite extensive research, no effective treatment for established DIC is currently available. Dexrazoxane is the only FDA-approved protective agent, but it has limitations. Recent studies have explored various potential therapeutic approaches, including natural drugs, endogenous substances, new dosage forms, and herbal medicines. However, the lack of experimental models incorporating pre-existing cancer limits the understanding of DIC pathophysiology and treatment efficacy. Conclusion: Cardiomyopathy, whether primary or secondary, poses a significant clinical challenge due to its varying etiologies and poor prognosis in advanced stages. Anthracycline-induced cardiomyopathy is a severe complication of chemotherapy, with doxorubicin being a notable contributor. Despite advancements in cancer therapies, the cardiotoxic effects of anthracyclines necessitate further investigation into effective preventive strategies and therapeutic interventions to improve patient outcomes.

16 May 2025 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SSSeema Sharma
Seema Sharma
IKInderpreet Kaur
Inderpreet Kaur
NDNaina Dubey
Naina Dubey
NGNeelima Goswami
Neelima Goswami
STSAMPAT SINGH TANWAR
SAMPAT SINGH TANWAR

12 January 2026 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
NDNaina Dubey
Naina Dubey
SSSeema Sharma
Seema Sharma
MGManish Mohan Ghadage
Manish Mohan Ghadage
STSAMPAT SINGH TANWAR
SAMPAT SINGH TANWAR

29 September 2026 in EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES
Verified
Journal Article
Closed access
STSAMPAT SINGH TANWAR
SAMPAT SINGH TANWAR
MCMahendra Chouhan
Mahendra Chouhan
RBRagni Bathre
Ragni Bathre
SSSeema Sharma
Seema Sharma
DLDevendra Singh Lodhi
Devendra Singh Lodhi
Pediatric emesis is a common and clinically significant problem associated with acute gastroenteritis, postoperative nausea, motion sickness, systemic infections, and drug-induced adverse effects. In children, recurrent vomiting may rapidly lead to dehydration, electrolyte imbalance, poor oral intake, reduced therapeutic compliance, and increased risk of hospitalization. These challenges highlight the need for age-appropriate, patient-centric antiemetic delivery systems that are effective, acceptable, and easy to administer. Conventional dosage forms, including syrups, tablets, and capsules, often fail to meet these requirements because of poor palatability, swallowing difficulties, dose inaccuracy, and administration challenges during active vomiting. Orodispersible films (ODFs) have emerged as a promising alternative owing to their rapid disintegration in the oral cavity, water-independent administration, ease of handling, portability, and potential for improved pediatric acceptability. Their formulation can be tailored through selection of suitable polymers, plasticizers, sweeteners, saliva stimulants, and taste-masking approaches to optimize drug release and patient compliance. This review highlights the clinical burden of pediatric emesis, examines the limitations of conventional antiemetic therapy, and discusses the growing rationale for ODF-based pediatric delivery systems. Particular attention is given to the need for age-appropriate formulations in children and the therapeutic advantages of film-based systems in improving medication adherence and ease of administration. Overall, ODFs represent a promising platform at the interface of pediatric clinical need and modern formulation science, with substantial potential to improve antiemetic therapy in children. Keywords: Pediatric emesis; orodispersible films; pediatric drug delivery; antiemetic therapy; age-appropriate formulations; oral thin films

26 March 2026 in EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES
Verified
Journal Article
Closed access
STSAMPAT SINGH TANWAR
SAMPAT SINGH TANWAR
Mahesh Kumar PosaMahesh Kumar Posa
Mahesh Kumar Posa
RKRavi Kumar Kota
Ravi Kumar Kota
VIV.T. Iswariya
V.T. Iswariya
PMP. Moulika
P. Moulika
SSSeema Sharma
Seema Sharma
Nanotechnology has transformed contemporary pharmaceuticals by providing nanoscale materials that enable precise drug delivery, controlled release, and targeted therapeutic applications. Silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) have emerged as exceptionally versatile agents owing to their adjustable size, shape, surface characteristics, and biocompatibility. This review offers an extensive examination of their pharmaceutical potential, emphasizing synthesis techniques namely, chemical, biological green, and physical methods and their impact on nanoparticle morphology, stability, and functionalization. Silver nanoparticles (AgNPs) exhibit significant antimicrobial efficacy and are extensively utilized in wound healing and infection management, whereas gold nanoparticles (AuNPs) are favoured in oncology, gene delivery, photothermal therapy, and diagnostics owing to their inertness and optical characteristics. Surface engineering techniques, including PEGylation and ligand conjugation (e.g., antibodies, aptamers, folic acid), enhance systemic circulation, targeting precision, and therapeutic efficacy. The review examines drug loading methodologies utilizing covalent and non-covalent interactions, as well as hybrid delivery systems such as liposomes and hydrogels, which facilitate improved entrapment efficiency and targeted delivery. Mechanistic understanding of drug release through diffusion, swelling, erosion, and degradation is underpinned by mathematical models such as Higuchi, Korsmeyer–Peppas, and zero-order kinetics. Recent innovations, including stimuli-responsive systems, microneedle patches, and AI-assisted formulation optimization are also examined. Notwithstanding substantial advancements, critical obstacles persist in large-scale production, nanotoxicity assessment, and regulatory authorization. Nonetheless, AgNPs and AuNPs signify a transformative advancement in pharmaceutical development, possessing the capacity to propel the forthcoming generation of personalized, adaptive, and intelligent drug delivery systems.